Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
Semaglutide keeps showing up in research on heart failure, especially in tough cases like frail patients with HFpEF (heart failure with preserved ejection fraction). The latest debate? How to actually measure if it works. Researchers Pandey, Kitzman, Domdey, and Kosiborod just fired off a letter in JACC Heart Fail, pointing out what’s missing: objective functional metrics and real body composition data.
JACC Heart Fail
by Pandey A, Kitzman D, Domdey A et al.
“Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment. Pandey A(1), Kitzman D(2), Domdey A(3), Kosiborod M(4). Author information: (1)University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: ambarish.pandey@utsouthwestern.edu. (2)Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. (3)Novo Nordisk A/S, Søborg, Denmark. (4)Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.”
Here’s the issue. Trials with semaglutide in HFpEF often rely on basic checklists or self-reported symptoms. That’s not enough if you want to know what’s really changing in the body. The authors argue for hard numbers—think step counts, grip strength, DEXA scans, muscle vs. fat breakdown. If semaglutide is moving the needle for frail HFpEF patients, researchers should prove it with data, not guesswork.
Why does this matter? Frail HFpEF is a beast. These patients are already on the edge. Any change in strength or muscle mass could be a game-changer, but only if we measure it right. Semaglutide’s known for shifting body weight, but is it burning muscle or fat? That’s a critical detail for researchers planning the next study.
Key takeaway: Peptide research isn’t just about “did it work”—it’s about how it worked, especially with complex conditions like HFpEF. Expect future semaglutide studies to step up their analytics.
For more details about this research compound, check out the semaglutide page. Looking for sources? Browse the vendor directory to see who’s supplying research-grade semaglutide.
Precision in measurement is the next frontier for peptide research.
Related Reading
Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
News · TransplantationTolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.